Raising Health The Science and Supply of GLP-1s with Chronis Manolis
9 snips
Jun 11, 2024 
Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, discusses the perspectives of payors and providers on anti-obesity medications, focusing on pricing and prior authorization challenges. The podcast delves into the scientific and supply aspects of GLP-1s, exploring the evolution of these drugs in healthcare, the importance of holistic support in drug prescriptions, strategies for optimizing pharmacy spend, and insights into incorporating these drugs into healthcare benefits packages.
AI Snips
Chapters
Transcript
Episode notes
GLP-1 Popularity and Evolution
- Social media significantly boosted GLP-1 popularity, increasing demand and payer concerns about abuse potential for weight loss.
- The development of weekly GLP-1s was a game changer, improving tolerability and increasing dosage frequency.
Future of GLP-1 Pricing
- Increased competition driven by high demand and innovation is expected to lower GLP-1 prices.
- Two major manufacturers could create a cartel-like situation, but multiple players would foster competition.
Coverage Recommendations for Anti-Obesity Drugs
- Cover anti-obesity drugs with medical wraparound programs that focus on behavior change.
- Consider time limits or reauthorization processes tied to weight loss progress.